Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice
Table 1
Summary of 11 cases of Parkinson’s disease psychosis.
Case #
Date of PD diagnosis
Date of initial visit
Age (y)
Sex
PD duration (y)
Medication history
Comorbid conditions
Primary complaint
1
2013
2016
79
M
5
Rasagiline
Depression
Tremor
CD/LD
2
2004
2016
71
M
14
Citalopram
Diabetes and hypertension
Generalized dyskinesias and tremor
Quetiapine
3
2011
2017
79
M
6
None
Hearing loss
Auditory hallucinations
4
2006
2018
71
M
12
CD/LD
Depression
Persistent false perceptions and daily hallucinations
Rasagiline
Sertraline
5
2006
2016
68
M
10
CD/LD
None noted
Difficulty walking; short-term memory loss
Selegiline
6
1999
NA
84
F
20
CD/LD
None noted
Persisting tremor and movement disorders
Pramipexole
Amantadine
Rasagiline
7
2016
2017
73
M
1†
CD/LD
Mild cognitive dysfunction
Symptoms consistent with RBD
Duloxetine
Depression and anxiety
8
NA
NA
68
M
9
Levodopa
None noted
Severe refractory tremors and motor fluctuations; evaluate for DBS
9
2002
2017
69
F
15
Levodopa
Depression and mild cognitive impairment
Tremors, bradykinesia, rigidity, and severe dyskinesia
Amantadine
Rotigotine
10
NA
NA
74
F
12
Levodopa
Depression and anxiety
Left upper-extremity tremor, decreased dexterity, and gait instability
11
NA
NA
76
M
4
None noted
Cognitive impairment
Shuffling gait, slowness, and drooling
At the time of evaluation. †Possible PD symptoms had been present for 6 years. CD/LD, carbidopa/levodopa; DBS, deep brain stimulation; PD, Parkinson’s disease; PDP, Parkinson’s disease psychosis; RBD, rapid eye movement sleep behavior disorder.
